Profil

Ooms Annie

See author's contact details
Main Referenced Co-authors
Cherdon, Céline  (4)
de Leval, Laurence  (4)
Defraigne, Jean  (4)
Drion, Pierre  (4)
Dogné, Jean-Michel (3)
Main Referenced Keywords
atherosclerosis (3); BM-573 (3); TP receptor (3); adhesion molecule (2); aspirin (2);
Main Referenced Unit & Research Centers
CREDEC (2)
CREDEC et GIGA-R (1)
FUNDP (1)
Giga-ULiège (1)
NTHC (1)
Main Referenced Disciplines
Cardiovascular & respiratory systems (2)
Biochemistry, biophysics & molecular biology (2)
Pharmacy, pharmacology & toxicology (1)

Publications (total 5)

The most downloaded
38 downloads
Cherdon, C., Rolin, S., de Leval, L., Drion, P., Defraigne, J.-O., Ooms, A., & Dogné, J.-M. (01 December 2009). The use of an adapted model allows contributing to the “Reduction” of mice used in experimental protocols: the case of the apoE–deficient (apo E-/-) mice in a model of atherosclerosis control [Poster presentation]. Belgian Council for Animal Science Symposium, Blankenberge, Belgium. https://hdl.handle.net/2268/27379

The most cited

18 citations (Scopus®)

Cherdon, C., Rolin, S., Hanson, J., OOMS, A., de Leval, L., Drion, P., Michiels, C., Pirotte, B., Masereel, B., SakalihasanN, N., DEFRAIGNE, J., & Dogné, J.-M. (2011). BM-573 inhibits the development of early atherosclerotic lesions in Apo E deficient mice by blocking TP receptors and thromboxane synthase. Prostaglandins and Other Lipid Mediators. doi:10.1016/j.prostaglandins.2011.03.001 https://hdl.handle.net/2268/87430

Bambi Nyanguile, S.-M., Hanson, J., OOMS, A., Alpan, L., Kolh, P., dogné, J.-M., & Pirotte, B. (July 2013). Synthesis and pharmacological evaluation of 2-aryloxy/arylamino-5-cyanobenzenesulfonylureas as novel thromboxane A2 receptor antagonists. European Journal of Medicinal Chemistry, 65, 32-40. doi:10.1016/j.ejmech.2013.04.033
Peer Reviewed verified by ORBi

Cherdon, C., Rolin, S., Hanson, J., OOMS, A., de Leval, L., Drion, P., michiels, C., Pirotte, B., Mullier, F., SakalihasanN, N., DEFRAIGNE, J., & Dogné, J.-M. (2011). BM-573 INHIBITS THE EARLY ATHEROSCLEROTIC LESIONS IN APO-E DEFICIENT MICE BY BLOCKING TP RECEPTORS AND THROMBOXANE SYNTHASE. In Congress of the International Society of Thrombosis and Hemostasis- 57th Annual SSC Meeting.
Peer reviewed

Cherdon, C., Rolin, S., Hanson, J., OOMS, A., de Leval, L., Drion, P., Michiels, C., Pirotte, B., Masereel, B., SakalihasanN, N., DEFRAIGNE, J., & Dogné, J.-M. (2011). BM-573 inhibits the development of early atherosclerotic lesions in Apo E deficient mice by blocking TP receptors and thromboxane synthase. Prostaglandins and Other Lipid Mediators. doi:10.1016/j.prostaglandins.2011.03.001
Peer Reviewed verified by ORBi

Cherdon, C., Rolin, S., de Leval, L., Drion, P., Defraigne, J.-O., Ooms, A., & Dogné, J.-M. (01 December 2009). The use of an adapted model allows contributing to the “Reduction” of mice used in experimental protocols: the case of the apoE–deficient (apo E-/-) mice in a model of atherosclerosis control [Poster presentation]. Belgian Council for Animal Science Symposium, Blankenberge, Belgium.

Cherdon, C., Rolin, S., Ooms, A., de Leval, L., Drion, P., Defraigne, J.-O., & Dogné, J.-M. (2009). Le bm-573, un antagoniste original du récepteur au thromboxane a2, réduit le développement des lésions athéromateuses chez des souris déficientes en apolipoprotéine e (apo e-/-) contrairement a l’aspirine [Paper presentation]. 21ème Journées Franco-Belges de Pharmaco chimie, 28 et 29 mai 2009, , Belgique, Mons, Belgium.
Peer reviewed

Contact ORBi